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Abstract
Background and Objectives: Depression is common among acute coronary syndrome (ACS) patients and is associated with
poor prognosis. Cardiac side effects of older antidepressants were well-known, but newer antidepressants are generally
thought of as safe to use in patients with heart disease. The objective was to assess rates of antidepressant use or
prescription to patients within a year of an ACS.
Methods: PubMed, PsycINFO, and CINAHL databases searched through May 29, 2009; manual searching of 33 journals from
May 2009 to September 2010. Articles in any language were included if they reported point or period prevalence of
antidepressant use or prescription in the 12 months prior or subsequent to an ACS for $100 patients. Two investigators
independently selected studies for inclusion/exclusion and extracted methodological characteristics and outcomes from
included studies (study setting, inclusion/exclusion criteria, sample size, prevalence of antidepressant prescription/use,
method of assessing antidepressant prescription/use, time period of assessment).
Results: A total of 24 articles were included. The majority were from North America and Europe, and most utilized chart
review or self-report to assess antidepressant use or prescription. Although there was substantial heterogeneity in results,
overall, rates of antidepressant use or prescription increased from less than 5% prior to 1995 to 10–15% after 2000. In
general, studies from North America reported substantially higher rates than studies from Europe, approximately 5% higher
among studies that used chart or self-report data.
Conclusions: Antidepressant use or prescription has increased considerably, and by 2005 approximately 10% to 15% of ACS
patients were prescribed or using one of these drugs.
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Introduction
Major depressive disorder (MDD) is present in approximately
20% of patients with coronary heart disease (CHD), including
acute coronary syndrome (ACS) patients [1,2]. Depression impacts
quality of life post-ACS [3], and many studies have linked MDD
or depressive symptoms to poor prognosis [4].
The rate of self-reported antidepressant use increased from
approximately 7% to 12% among US adults from 1996 to 2005
[5]. In Europe, just under 4% of respondents from 6 countries
surveyed between 2001 and 2003 reported 12-month antidepres-
sant use [6]. The potential for tricyclic antidepressants (TCAs) and
monoamine oxidase inhibitors (MAOIs) to cause serious and
potentially fatal side effects has limited their use in cardiac
populations [7,8]. On the other hand, selective serotonin reuptake
inhibitors (SSRIs) have generally been accepted as safe in cardiac
patients because they appear to lack these side effects [9–11].
Several clinical trials have examined the efficacy of SSRIs in
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e27671cardiac populations [9,10,12–14] and have reported effect sizes
that are similar to those from non-cardiac populations [15–18].
Concerns have been raised in recent years, however, about
previously unrecognized adverse side effects of SSRIs potentially
relevant to CHD patients [19–21], as well as potentially dangerous
interactions between SSRIs and commonly used cardiac medica-
tions [22–26].
No systematic reviews have characterized the rate of antide-
pressant use or prescription in ACS patients, which was the
objective of this review.
Methods
Reporting of the study was based on guidelines established by
the Meta-analysis of Observational Studies in Epidemiology
statement [27].
Data Sources and Searches
Potentially eligible articles were identified from the PubMed,
PsycINFO, and CINAHL databases, searched on May 29, 2009.
Search strategies (Supporting Information S1) were designed to
identify articles that reported on ACS patients in association with
depression or antidepressant use. In addition, manual searching of
33 cardiology, psychiatry, and general medicine journals (Sup-
porting Information S2) was conducted to identify articles
published subsequent to the electronic database search (May 1,
2009 to September 30, 2010).
Study Selection
Eligible articles included published articles of original research
in any language that reported point or period prevalence of
antidepressant use or prescription in the 12 months prior or
subsequent to an ACS, defined as unstable angina, non-ST-
elevation myocardial infarction (MI), or ST-elevation MI, for at
least 100 patients. Antidepressants included SSRIs, serotonin-
norepinephrine reuptake inhibitors (SNRIs), TCAs, MAOIs, and
atypical antidepressants. Studies with data on only a single
antidepressant class were excluded. Studies with inclusion criteria
that required antidepressant use or a condition associated with
antidepressant use (e.g., depressive disorders) and studies that
utilized antidepressants as part of an intervention were excluded
unless they reported data on antidepressant prescription or use for
all patients assessed for study eligibility. Non-published studies,
studies published in abstract form only, letters, editorials, and case
series or case reports were excluded. When multiple articles were
published on the same cohort or portions of the same cohort, the
article with the most complete data was included. Studies with
mixed populations were included if data for ACS patients were
reported separately.
Two investigators independently reviewed articles for eligibility.
If either deemed an article potentially eligible based on title/
abstract review, then a full-text review was completed. Disagree-
ments after full-text review were resolved by consensus of three
investigators, including the two reviewers. Non-English articles
were evaluated by one investigator with the assistance of a
translator. As necessary, authors were contacted to clarify
information relevant to determining eligibility.
Data Extraction
Two investigators independently extracted data from included
studies into a standardized spreadsheet with discrepancies resolved
via consensus. Extracted data included the study setting (North
America, Europe, other), study inclusion/exclusion criteria,
sample size, prevalence of antidepressant prescription/use (total
and by antidepressant class), method of assessing antidepressant
prescription/use, and time period of assessment. Methods of
assessment were classified as administrative database, review of
medical record, observation of medication containers, and patient
self-report. The time period was recorded as the midpoint of the
Figure 1. Flow Diagram of Study Selection Process.
doi:10.1371/journal.pone.0027671.g001
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was assessed at multiple time points for the same patients, the time
point closest to the index ACS was used. Authors were contacted
as necessary for clarification.
One included article [28] used province-wide administrative
data from Ontario, Canada to determine the percentage of post-
MI patients aged 65 or older who were prescribed an
antidepressant in the first 6 months post-MI. Antidepressant
prescriptions were reported on a quarterly basis from the second
calendar quarter of 1993 to the first calendar quarter of 2002.
Numerical data were provided for the first and last quarters of the
study, with scatterplot data provided for other quarters. Original
data were no longer available (personal communication, Muham-
mad Mamdani, May 17, 2010). Therefore, two investigators
estimated quarterly prevalence data from the published scatter-
plot, and all estimates were within 0.1% of each other. For the
purposes of the present study, data are presented for one calendar
quarter per year (second quarter 1993 through second quarter
2001).
Data Synthesis and Analysis
Included studies were evaluated to determine if there was
sufficient clinical and methodological similarity to support a
pooled meta-regression of the rate of antidepressant prescription
or use over time, factoring in setting (North America versus
Europe and other) and method of assessment (administrative data
versus self-report or chart review). However, excluding the study
by Benazon et al. [28] that provided quarterly data over an
approximately 10-year period, there were too few studies overall
and not enough coverage across time, setting, and assessment
method to reasonably pool all of the data from the other studies
with meta-regression. Therefore, a qualitative synthesis was done
for all studies in the review and a quantitative meta-analysis for a
subset of studies.
Specifically, we determined that there was a sufficient number
of studies to assess the association of time and setting with
antidepressant prescription or use among studies that ascertained
rates using non-administrative data (e.g., self-report or chart
review) with the midpoint of data collection from October 1997 or
Table 1. Characteristics of Studies Included in the Systematic Review.
First Author, Year Country Patients N % MI
Mean
Age
(Years)
%
Male
%
White
Years of
Study
Benazon, 2005
a Canada MI admission, survived $6 months postdischarge;
$65 years; no MI 3 years prior to index MI
1637–2231 100% NR NR NR 1993–2002
Grunau, 2006 Canada MI admission; $66 years 5559 100% NR NR NR 1994–1995
Lesperance, 2000 Canada Unstable angina admission; documented CAD 430 0% 62 71% NR 1994–1996
Parakh, 2008 USA MI admission 284 100% 65 57% 87% 1995–1996
Sauer, 2001 USA First MI admission; 30–65 years 653 100% 52
b 68%
b NR 1995–1997
Lauzon, 2003 Canada MI admission 464 100% 60
c 79%
c 96%
c 1996–1998
Grace, 2005 Canada ACS admission 913 53% 62 65% NR 1997–1999
Rumsfeld, 2003 USA ACS admission 1957 50% 65 98% 89% 1998–1999
Frasure-Smith, 2008 Canada ACS admission; cardiac catherization 804 NR 60 81% NR 1999–2001
Corser, 2006 USA ACS admission 521 NR 60 64% 84% 2002–2003
Mallik, 2006 USA MI admission 2361 100% 61 68% NR 2003–2004
Grace, 2008 Canada ACS admission 505 NR 62 77% 84% 2003–2004
Huffman, 2006 USA MI admission 131 100% 62 80% NR 2003–2005
Zimmermann-Viehoff, 2010 Sweden Women ,65 years admitted for ACS 266 36% 56 0% NR 1991–1993
Monster, 2004 Denmark First MI admission 8887 100% 72 62% NR 1994–2002
Dickens, 2007 UK MI admission 507 100% 59
d 71%
d 95%
d 1997–1999
Kaptein, 2006 Netherlands MI admission 475 100% 61 81% NR 1997–2000
Pitzalis, 2001 Italy MI admission ,70 years 128 100% 54
e 86%
e NR 1998–2000
Sorensen, 2005 Denmark MI admission ,70 years 889 NR 60 73% NR 1999–2000
Nakatani, 2005 Japan MI admission 2509 100% 64 77% NR 1999–2003
Costa Dias, 2005 Portugal ACS admission 240 71% 59 85% NR 2001–2002
Bhattacharyya, 2007 UK ACS admission; 18 to 90 years with paid
employment
126 NR 55 88% 85% 2001–2004
Parker, 2008 Australia ACS admission 489 65% 66 70% NR 2001–2003
Wong, 2008 NZ ACS admission 276 63% 64 71% NR 2005
ACS=acute coronary syndrome; CAD=coronary artery disease; MI=myocardial infarction; NR=Not reported; NZ=New Zealand; UK=United Kingdom; USA=United
States of America.
aProvincial database with quarterly data evaluated from 2
nd quarter of 1993 to 1
st quarter of 2002.
bExcluding 5 patients with ‘‘other’’ antidepressant use.
cBased on 550 patient enrolled in the study at index hospitalization.
dBased on 527 patients enrolled in study.
eBased on 103 patients.
doi:10.1371/journal.pone.0027671.t001
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prior to October 1997 or to include studies with administrative data.
For this subset of studies, we first performed an overall meta-
analysis and then proceeded to fit meta-regressions controlling for
region and for time. The I
2 statistic was used to assess heterogeneity
for the meta-analysis [29], and radial and funnel plots were generated
to assess model assumptions. The R statistical software was used to
analyze the results via the metafor library [30,31]. The main meta-
regression model was fit using Restricted Maximum Likelihood
estimators with the rate of antidepressant usage as the outcome.
Results
Search Results
The database search yielded 1,619 unique citations (Figure 1),
including 666 selected for full text review and 35 that met
inclusion criteria. Of the 35 eligible articles, 12 reported on the
same cohort, leaving 23 unique articles for review. One additional
eligible article was identified through manual search, resulting in a
total of 24 included articles [28,32–54].
Characteristics of Included Studies
As shown in Table 1, the 24 included studies reported data on
antidepressant prescription or use from April 1993 through
December 2005. Data from one published study by Benazon
et al. [28] reported antidepressant prescription rates in the 6
months following hospital discharge for patients surviving at least 6
months from the 2
nd quarter of 1993 to the 1
st quarter of 2002.
There were 13 studies from North America, 8 from Europe, and 1
each from Japan, Australia, and New Zealand. As shown in
Table 2, only 3 studies used data from administrative databases,
including the Benazon et al. study [28]. One study reviewed
patients’ medication containers, and 20 used self-report, medical
chart review, or a combination of the two. Sample sizes in the 3
studies that used administrative data ranged from 1,637 to 8,887
patients. For other studies, the range was from 126 to 2,509
patients. Of the 24 studies, 15 reported antidepressant prescription
or use during the index ACS admission or at discharge, 4 reported
pre-admission prescription or use, and 5 studies reported post-
ACS prescription or use. One study reported antidepressant use
among women aged ,65 years [44], 2 studies did not report
gender composition [28,32], and the rest of the studies included
predominantly males (57% to 98%).
Prevalence of Antidepressant Prescription or Use
As shown in Figure 2, the rate of patients prescribed or using
antidepressants increased from 1993 to 2005. Results from the
Benazon et al. study are shown separately for 9 cohorts/years
Table 2. Antidepressant Prescription or Use in Included Studies.
First Author, Year Country
Method of Antidepressant
Use Assessment
Time of Antidepressant
Use Assessment
N (%) with
Antidepressant
Classes of Antidepressants
Used
Benazon, 2005
a Canada Administrative database Within 6 months post-MI 128–357 (8% to 16%) 1993, Q2: SSRI=29; TCA=106.
2002, Q1: SSRI=217; TCA=126
Grunau, 2006 Canada Administrative database Within 12 months pre-MI 471 (9%) NR
Lesperance, 2000 Canada Chart review Discharge 18 (4%) NR
Parakh, 2008 USA Chart review Discharge 14 (5%) NR
Sauer, 2001 USA Self-report Within 1 week pre-MI 18 (3%) SSRI=13; Other=5
Lauzon, 2003 Canada Self-report 12 months post-MI 13 (3%) NR
Grace, 2005 Canada Self-report During admission 42 (5%) NR
Rumsfeld, 2003 USA Chart review Discharge 254 (13%) NR
Frasure-Smith, 2008 Canada Medicine containers 2 months post-ACS 68 (8%) NR
Corser, 2006 USA Chart review Discharge 61 (12%) NR
Mallik, 2006 USA Chart review Discharge 231 (10%) NR
Grace, 2008 Canada Self-report 9 months post-ACS 48 (10%) SSRI=27; TCA=6; SNRI=8;
Other=7
Huffman, 2006 USA Chart review During admission 16 (12%) NR
Zimmermann-Viehoff, 2010 Sweden Chart review/Self-report During admission 0 (0%) 0
Monster, 2004 Denmark Administrative database Within 90 days pre-MI 540 (6%) SSRI=289; Other=251
Dickens, 2007 UK Chart review Discharge 21 (4%) NR
Kaptein, 2006 Netherlands Self-report 3 months post-MI 15 (3%) NR
Pitzalis, 2001 Italy Self-report During admission 0 (0%) 0
Sorensen, 2005 Denmark Chart review Discharge 39 (4%) NR
Nakatani, 2005 Japan Chart review/Self-report During admission 124 (5%) NR
Costa Dias, 2005 Portugal Self-report Prior to admission 2 (1%) NR
Bhattacharyya, 2007 UK Chart review During admission 8 (6%) NR
Parker, 2008 Australia Self-report During admission 32 (7%) SSRI=17; TCA=12; MAOI=4
Wong, 2008 NZ Self-report During admission 11 (4%) NR
MAOI=monoamine oxidase inhibitor; NR=Not reported; NZ=New Zealand; Q1=1
st quarter; Q2=2
nd quarter; SNRI=serotonin-norepinephrine reuptake inhibitor;
SSRI=selective serotonin reuptake inhibitor; TCA=tricyclic antidepressant;
aProvincial database with quarterly data evaluated from 2
nd quarter of 1993 to 1
st quarter of 2002.
doi:10.1371/journal.pone.0027671.t002
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reported substantially higher rates than studies from Europe.
Based on self-report or chart review, the only study from North
America from 1995 or earlier [33] reported a rate of 4.2%,
whereas the only pre-1995 European study, which reported on
women under age 65 from Sweden, reported that no patients were
using antidepressants upon admission for ACS [44]. One other
study, which reported on Italian patients under the age of 70
admitted for MI from 1998 to 2000, similarly reported that no
patients were using antidepressants at the time of admission [48].
Rates of antidepressant use or prescription among North
American studies that used self-report or chart review from 2000
onward ranged from 9.5% to 13.0%, compared to 0.8% to 6.5%
among non-North American studies in the same time period.
Among studies of administrative databases, rates in North
America ranged from 7.8% to 9.9% from 1993 to 1995 and
increased to 13.8% to 14.8% in studies from 2000 onward. The
only European study that used administrative data was a Danish
study that reported a rate of 6.1% of 8,887 patients with
antidepressant prescriptions in the years 1994 to 2002 [45].
During approximately the same period, rates reported by Benazon
et al. from Ontario, Canada increased from 7.8% in the second
quarter of 1993 to 15.7% by the first quarter of 2002 (Benazon
data in Figure 2 through the second quarter of 2001) [28].
Only five studies reported rates of use or prescription by
antidepressant class 28,35,42,45,53], so analysis of rates by class
was not possible. However, in the study by Benazon et al. [28] the
percentage of patients prescribed an SSRI increased five-fold from
approximately 2% in the second quarter of 1993 to approximately
10% in the first quarter of 2002. TCA prescription, on the other
hand, remained stable at approximately 6% across the study
period.
There were 17 studies that assessed prevalence of antidepressant
prescription or use using non-administrative databases with study
midpoints of October 1997 onward and were included in the
meta-analysis, including 8 studies from North America [36–43]
and 9 studies from Europe [46–49,51,52], Japan [50], Australia
[53], or New Zealand [54]. Overall, the random effects model
estimate for antidepressant use for all 17 studies was 6.1% (95%
confidence interval (CI) 4.3% to 7.9%). However, the I
2 statistic
was extremely large (95.7%), indicating a substantial amount of
between study heterogeneity, which was also seen in the funnel
plot (Figure 3). Meta-regression was done with setting (North
American versus Europe and other) and time (year of midpoint of
data collection) as predictor variables. The estimated difference
between rate of use in North America versus Europe and other
was 5.1% (95% CI 2.5% to 7.8%, p,0.001). In addition, the rate
of use increased by approximately 0.5% per year (95% CI 0.0% to
1.1%, p=0.065). Adjusting for setting and time accounted for
50% of heterogeneity in prevalence between studies from the
overall meta-analysis, and the funnel plot reflected less structured
heterogeneity and better model fit (Figure 4). Results did not
change if transformations of the raw proportions (arcsin and log)
were modeled.
Discussion
Consistent with general population trends [5,6,55] the prescrip-
tion or use of antidepressants has risen dramatically among ACS
Figure 2. Prevalence of Antidepressant Use in ACS Patients. Studies are grouped by geographic region and sorted by midpoint of data
collection period. Benazon et al. [28] rates are denoted with grey markers. Error bars are +/21.96 standard errors, and marker sizes are weighted
according to the inverse of the squared standard error. *Medication information was abstracted from patient charts but only prescriptions actually
filled were included.
{Study reported, ‘‘only two patients were taking antidepressants prior to hospitalization,’’ which was coded as being assessed at
hospital admission.
doi:10.1371/journal.pone.0027671.g002
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heterogeneity in results, overall, rates of antidepressant prescrip-
tion or use increased from less than 5% prior to 1995 to 10–15%
after 2000. One study that tracked antidepressant prescribing to
post-MI patients using province-wide administrative data from
Ontario, Canada found that the percentage of patients with an
antidepressant prescription in the 6 months following hospital
discharge increased from 7.8% in 1993 to 15.7% by 2002 [28]. In
the meta-regression, there was an increase of approximately 0.5%
per year in studies that used non-administrative data between
1997 and 2005. As with general population data, the rate of
antidepressant prescription or self-reported use was notably higher
in North America than in other parts of the world, primarily
Europe, with an estimated difference of approximately 5.1%
among studies from 1997 onward that used self-report or chart
data to establish usage rates.
There has been a striking increase in the use of antidepressant
medications in the general population in the past two decades, due
in large part to a significant increase in the prescribing of
antidepressant medications by nonpsychiatrists [55]. One reason
for this trend is likely to be the perception that antidepressants are
safe to use even in patients with medical comorbidities, including
heart disease [56]. Based on the results of several studies [9,10,12]
including post hoc analysis of the Enhancing Recovery in
Coronary Heart Disease Patients (ENRICHD) study [57], it has
been concluded that SSRIs are safe to use in patients with heart
disease [58]. Consistent with this, a recent study of antidepressant
use in primary care notes ‘‘…the preponderance of evidence
suggests that it is not necessary to be overly cautious when
prescribing for patients who have medical comorbidities. Most
studies have demonstrated that SSRIs are safe and effective in
persons who have both CAD (coronary artery disease) and stroke’’
[56]. The side effects of the older antidepressants, however, limited
their use in heart disease. TCAs can increase heart rate, produce
orthostatic hypotension, decrease heart rate variability, prolong
cardiac conduction, and trigger potentially lethal ventricular
arrhythmias [9]. MAOIs can also produce orthostatic hypoten-
sion, but their potential to cause hypertensive crisis in patients who
ingest tyramine-containing food or certain other drugs is the most
concerning of their cardiovascular side effects [59].
The increased use of antidepressant drugs in ACS patients in
recent years may not only reflect greater comfort with these
agents, but also a greater awareness of the burden of depression in
patients with CHD [2,4]. Over the years, many informal calls have
been made for increased depression treatment in heart disease
patients, and recently an AHA Science Advisory recommended
routine depression screening for all heart patients in order to
increase the treatment rate [58]. Indeed, the problem of under-
diagnosed and under-treated depression has been recognized as an
important public health issue outside of cardiovascular care
settings, and increasing depression treatment, including antide-
pressant prescribing, has been prioritized [60].
Whether depression in ACS patients is under-treated despite the
more widespread prescription or use of antidepressants docu-
Figure 3. Heterogeneity of Unadjusted Prevalence Estimates. The funnel plot shows individual study prevalence estimates (x-axis) plotted
against estimated standard errors (y-axis). The white cone inside the gray region indicates a 95% probability region that points would be expected to
fall into assuming no heterogeneity and no publication bias. The North American studies are indicated by the filled circles and the non-North
American studies are indicated by the 6symbols.
doi:10.1371/journal.pone.0027671.g003
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antidepressants from appropriate use or overuse is beyond the
scope of this systematic review. Nonetheless, it should be noted
that overuse occurs when the risk of potential harm of using a drug
outweighs the likely benefits for some patients. The overuse of
antidepressants among populations who are unlikely to benefit
meaningfully, is well-documented [61]. In the context of ACS, it
should be pointed out that as antidepressant use increases, the
potential for harm, even if small, also increases. Although the
SSRIs appear to have few direct adverse cardiovascular effects,
clinically important drug-drug interactions may be encountered
with more widespread use in ACS patients since many of these
drugs inhibit hepatic cytochrome P450 isoenzymes [62], which are
involved in the metabolism of many cardiac drugs. The safety of
SNRIs in ACS patients has not been as well-studied, which is
important to consider since these drugs can increase blood
pressure and heart rate [63]. It should be noted that recent reports
raise persistent concern about potential adverse cardiovascular
effects of antidepressant drugs [20,21,25,26,64–66], suggesting
that additional studies that evaluate cardiovascular side effects of
antidepressant drugs in greater numbers of patients followed for
longer time periods may be warranted.
There are limitations that should be considered in interpreting
the results of this study. First, although the search that was
conducted was broad and resulted in the review of more than 600
full-texts of articles, it is possible that some studies that reported on
the rate of antidepressant use or prescription may not have been
identified. Second, there are limitations in the methods used by
original studies to ascertain the rate of antidepressant prescription
or use. It is well-known, for instance, that self-report methods,
which were used in a number of the studies we reviewed, tend to
underestimate rates of prescription and use [67–69].
There were not enough studies from North America versus
Europe and that used administrative data versus self-report or
chart data across the time frame of the studies we reviewed to
synthesize all data quantitatively. Thus, we were only able to
estimate the prevalence quantitatively using non-administrative
database studies that were conducted from 1997 onward. With
only 17 studies included in the meta-analysis and limited
information on some of these, we were not able to adjust for
studycharacteristicsbeyondsetting and time,suchaspatientgender
or age. Even after adjusting for these variables, there was a
substantial amount of heterogeneity between studies. Thus, the
meta-regression results should be interpreted with caution.
Additionally, very few studies provided information on the classes
of antidepressants prescribed, which did not permitspecific analysis.
Furthermore, no studies with data on antidepressant prescription or
use since 2005 were available, so it is not known whether or not
prescription rates have continued to increase beyond the rates
reported in the studies reviewed. Finally, the protocol for this review
was not registered prior to initiating work on the review.
In summary, the results of this systematic review showed that the
rate of antidepressant prescriptions and use has risen dramatically in
recent years among ACS patients and, as in the general population,
tends to be higher in North America than in other parts of the world.
The fact that by 2005 between 10% and 15% of ACS patients were
Figure 4. Heterogeneity of Adjusted Prevalence Estimates. The funnel plot shows the residuals from the meta-regression on setting and time
(x-axis) plotted against estimated standard errors (y-axis). The white cone inside the gray region indicates a 95% probability region that points would
be expected to fall into assuming the assumptions of the meta-regression were valid. The North American studies are indicated by the filled circles
and the other studies are indicated by the 6symbols.
doi:10.1371/journal.pone.0027671.g004
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receiving treatment for depression, which is clearly an important
problem in patients with heart disease. Alternatively, this prevalence
of antidepressant use raises the possibility that antidepressants are
being used by some ACS patients who may not benefit meaningfully
despite being exposed to the possibility of adverse effects of the drugs
themselves or to clinically significant drug-drug interactions. Careful
consideration needs to be given to the balance between potential
benefits and harms in prescribing antidepressant medications to
patients with heart disease.
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